トリグリセライド、HDLと動脈硬化

出版社: フジメディカル出版
著者:
発行日: 2001-11-01
分野: 臨床医学:内科  >  血管
電子書籍版: 2001-11-01 (初版)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

4,620 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,310 円(税込)

商品紹介

コレステロールが粥状動脈硬化に基づく血管病、特に冠動脈疾患の主要な危険因子として広く認められてきたのに対し、中性脂肪の立場はきわめてあいまいであり続けてきた。その理由の一つは、血中のLDLコレステロールの濃度が虚血性心臓病の発症に明確なcurvilinearの関連を示すのに大使、トリグリセライドの方はいわゆるTG-richリポ蛋白としての普通の組成を持つVLDLやカイロミクロンが動脈硬化のリスクに繋がらない、したがってコレステロールのようにはっきりした濃度依存性がみられないことである。(「序」より)

目次

  • トリグリセライド、HDLと動脈硬化
    山本章/編

    ―目 次―
    1 トリグリセライド、HDLとコレステロール
    2 見直されるトリグラセイド、HDLの意義
    3 リスクファクターとしてのトリグリセライド
    4 multiple risk factor症候群
    5 トリグリセライド、HDLコレステロールと動脈硬化
    6 HDLの疫学について
    7 combined hyperlipidemia
    8 combined hyperlipidemiaの成因
    9 TG-richリポ蛋白の代謝
    10 トリグリセライド代謝、HDL代謝と調節遺伝子
    11 トリグラセイド、HDLと内皮細胞機能、マクロファージ
    12 高トリグリセライド血症および低HDLコレステロール血症における凝固線溶反応
    13 リポ蛋白リパーゼ欠損症、肝性トリグリセライドリパーゼ欠損症
    14 アルコールとIV型、V型高脂血症
    15 糖尿病と高トリグリセライド血症
    16 食後の高脂血症
    17 女性ホルモンとトリグリセライド代謝、高脂血症
    18 高トリグリセライド血症の治療
    19 IDL、レムナント測定法
    20 座談会『トリグリセライドとコレステロール、虚血性心疾患のリスクファクター』

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 ◎ トリグリセライド、HDLとコレステロール

P.21 掲載の参考文献
1) 山本 章ほか:高脂血症における血清燐脂質とその脂肪酸組成について. 臨床病理 23:13-19, 1974
3) Boren J et al:Studies on the assembly of apolipoprotein B-100 and B-48-containing very low density lipoproteins in McA-RH 7777cells. J Biol Chem 269:25879-25888, 1994
5) 山本 章:血漿トリグリセライド代謝におけるリポ蛋白リパーゼと肝性トリグリセライドリパーゼの役割. 動脈硬化 24:147-153, 1996
7) Maeda N et al:Targeted disruption of the apolipoprotein C-III gene in mice resuts in hypotriglyceridemia and protection from the postprandial hypertriglyceridaemia. J Biol Chem 269:23610-23616, 1994
13) Ohnishi T et al:Rapid purification of humam plasma lipid transfer proteins. J Lipid Res 31:397-406, 1990
14) 池田康行ほか:高トリグリセライド血症と small dense LDL. Ther Res 19:3455-3465, 1998
19) Nie L, Wang J, Clark LT et al:Body mass index and hepatic lipase gene(LIPC) polymophism jointly influence postheparin plasma hepatic lipase activity. J Lipid Res 39:1127-1130, 1998
21) Ashley DT et al:Factors influencing the ability of high-density lipoproteins to inhibit the expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscl Thromb Vascul Biol 18:1450-1455, 1998

2 ◎ 見直されるトリグセライド、HDLの意義

P.27 掲載の参考文献

3 ◎ リスクファクターとしてのトリグリセライド

P.42 掲載の参考文献
5) 中村治雄:原発性高脂血症の疫学. 高脂血症-治療と病態(垂井清一郎, 松沢佑次 編), 厚生省特定疾患「原発性高脂血症」調査研究班事務局, 1998, p44-55
8) Sacks MF, Pfeffer MA, MoyeLA et al:The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
18) 坂上太郎, 平野 勉, 芳野 原ほか:レムナント-リポ蛋白におよぼす糖尿病性腎症の影響. 糖尿病 42:439-446, 1999
21) Nakajima K, Saito T, Tamura A et al:A new assay method for the quantification of cholesterol in remnant-like particles in human serum using monoclonal anti-apo B100 and anti-apo A-1 immunoaffinity mixed gels. Clin Chim Acta 223:53-71, 1993
23) Kazumi T, Kawaguchi A, Hayakawa M et al:Remnant lipoprotein cholesterol (RLP-C) is part of insulin resistance syndrome. Diabetes 47 (Supple. 1):A32, 1998
26) Devaraji S, Vega G, Lanse R et al:Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am J Med 104:445-450, 1998
28) Syvanne M, Hilden H, Taskinen MR:Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. J Lipid Res 35:15-26, 1994
30) Coresh J, Kwiterorich PO, Smith HH et al:Association of plasma triglyceride concentration and LDL particle diameter, density and chemical composition with premature coronary artery disease in men and women/J Lipid Res 34:1687-1693, 1993
31) Galeano NF, Milne R, Marcel YL et al:Apolipoprotein-B structure and receptor recognition of triglyceride-rich low density lipoprotein(LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 269:511-519, 1994
32) Chen GC, Liu W, uchateau P et al:Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins(LDL). Association of altered proteolytic accessibility with decreased receptor binding of LDL subspecies from hypertriglyceridemic subjects. J Biol Chem 269:29121-29128, 1994
33) Galeano NF, AL-Haideri M, Keyserman F et al:Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites:a potential mechanism for increased atherogenicity. J Lipid Res 39:1263-1273, 1998

4 ◎ multiple risk factor症候群

P.53 掲載の参考文献
1) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
6) 垂井清一郎:日本人における高脂血症とその合併症. 動脈硬化 18:1-16, 1990
7) 板倉弘重ほか(J-LIT研究会):J-LIT有効性・安全性, 一次予防, 二次予防, 第33回日本動脈硬化学会総会で発表
10) Kuriyama H, Yamashita S, Shimomura I et al:Enhanced expression of hepatic acyl-CoA synthase and microsomal triglyceride transfer protein mRNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology 27:557-562, 1998
12) Stromblad G, Bjorntorp P:Reduced hepatic insulin clearance in rats with dietary induced obesity. Metabolism 35:323, 1986
13) Jiao S, Matsuzawa Y, Matsubara K et al:Abnormalities of plasma lipoproteins in a new genetically obese rat with non-insulin-dependent diabetes mellitus (Wistar fatty rat). Int J Obes 15:487, 1991
16) Arai T, Hirano K, Yamashha S et al:Marked increase of plasma cholesteryl ester transfer protein in obese subjects-correlation between plasma CETP activity, high density lipoprotein-cholesterol levels and body fat distribution. Arterioscl Thromb 14:1129-1136, 1994
20) Altman TJ, Glazier AM, Wallace CA et al:Identification of Cd36(Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 21:76-83, 1999

5 ◎ トリグリセライド、HDLコレステロールと動脈硬化

P.71 掲載の参考文献
1) Gofman J, Strisower B, de Lalla O et al:Index of coronary artery atherogenesis. Mod Med:21:119-140, 1953
8) Kukita H, Hiwada K:Epidemiology of hypertriglyceridemia in relation to atherosclerotic cardiovascular diseases. Current Advances in Triglycerides and Atherosclerosis (Yamamoto A, Nakamura H, Nakai T ed), Churchill Livingstone Japan, Tokyo, 1994, pp11-26
11) 山本 章(日本人における高脂血症調査研究班):日本人の血清脂質(HDL). 動脈硬化 12:1345-1349, 1985
12) Castelli WP:Cholesterol and lipids in the risk of coronary artery disease. The Framingham Heart Study. Canad J Cardiol 4 (Suppl A):5a-10a, 1988
16) 茎田仁志, 日和田邦男:冠動脈硬化症の疫学における高トリグリセライド血症の意義. Therap Res 14:551-558, 1991
17) The international Committee for the Education of Hypertriglyceridemia as a Vascular Risk Factor:the Hypertriglyceridemia risk and management. Am J Cardiol 68 (Suppl A):1-42, 1991
18) Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel II):Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high cholesterol in adults. JAMA 269:3015-3023, 1993
19) NIH Consensus Development Panel on Triglyceride, High Density Lipoprotein, and Coronary Heart-Disease:Triglyceride, high-density lipoprotein and coronary heart disease. JAMA 269:505-510, 1993
21) 山本 章, 石川勝憲, 松澤佑次ほか:動脈硬化症における血清リポ蛋白異常について. 動脈硬化 3:261-265, 1975
28) Jeppesen J, Hein oH, Suadicani P et al:Low triglycerides-high high-density lipoprotein cholesterol and rich of ischemic heart disease. Arch Intern Med 161:361-366, 2001
33) Executive Summary of The Third Report of The National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
36) 多田紀夫:食後高脂血症と高レムナント血症-脂肪負荷試験の意義. 動脈硬化 27:319-325, 2000

6 ◎ HDLの疫学について

P.81 掲載の参考文献
1) 三井田孝:コレステロール逆転送系の分子機構. 日本臨床 59 (増2):463-467, 2001
2) Miller NE, Thelle DS, Forde OH et al:The Tromso heart-study. High-density lipoprotein and coronary heart-disease:a prospective case-control study. Lancet i:965-968, 1977
4) Gordon DJ:Epidemiology of lipoproteins. Lipoproteins in health and disease. (Betteridge DJ, Illingworth DR, Shepherd J eds) , 1st ed, Arnold, London, 1999, pp587-595
5) Foody JM, Ferdinand FD, Pearce GL et al:HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery:20-year experience from the Cleveland Clinic Foundation. Circulation 102 (suppl III):90-94, 2000
7) 垂井清一郎:日本人における高脂血症とその合併症. 動脈硬化 18:1-16, 1990
10) 藤島正敏:日本人の脳血管障害. 日内会誌 85:1407-1418, 1996
12) Assmann G, Cullen P Schulte H:The Munster Heart Study(PROCAM):Results of follow-up at 8 years. Eur Heart J 19 (Suppl A):A2-11, 1998
18) Miida T, Yamaguchi T, Tsuda T et al:High pre β 1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet. Atherosclerosis 138:129-134, 1998
19) Miida T, Sakai K, ozaki K et al:Bezafibrate increases pre β 1-HDL at the expense of HDL2b in hypertriglyceridemia. Arterioscler Thromb Vasc Biol 20:2428-2433, 2000

7 ◎ combined hyperlipidemia

P.95 掲載の参考文献
2) Nikkila EA, Aro A:Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet 1:954-959, 1973
5) Kane JP, Havel RJ:Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. The metabolic and molecular basis of inherited disease (Scriber CR et al ed) , 7th ed, McGraw-Hill Inc. , NY, 1995, pp 1981-2030
8) Yang WS, Nevin DN, Iwasaki L et al:Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J Lipid Res 37:2627-2637, 1996
9) Pihlajamaki J, Rissanen J, Valve R et al:Different regulation of free fatty acid levels and glucose oxidation by the Trp64Arg polymorphism of the beta3-adrenergic receptor gene and the promoter variant(A-3826G) of the uncoupling protein l gene in familial combined hyperlipidemia. Metabolism 47:1397-1402, 1998
10) Pihlajamaki J, Miettinen R, Valve R et al:The Pro 12A1a substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia. Atherosclerosis 151:567-574, 2000
12) Allayee H, Dominguez KM, Aouizerat BE et al:Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. J Lipid Res 41:245-252, 2000
15) Aouizerat BE, Allayee H, Rotter JI et al:Identification of TNFRSFIB as a novel modifier gene in familial combined hyperlipidemia. Hum Mol Genet 9:2067-2074, 2000
18) Geurts JM, Janssen RG, van Greevenbroek MM et al:Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia. Am J Hum Genet 58:812-822, 1996
21) 齋藤 康:安房地区における家族性複合型高脂血症の疫学調査. 厚生省特定疾患調査 研究原発性高脂血症調査研究班平成9年度研究報告(班長 北 徹), 1998, pp7-12
22) 齋藤 康:安房地区における家族性複合型高脂血症の疫学調査. 厚生省特定疾患調査 研究原発性高脂血症調査研究班平成10年度研究報告(班長 北 徹), 1999, pp5-9
23) 垂井清一郎:高脂血症の分類と診断基準. 厚生省特定疾患調査研究原発性高脂血症 調査研究班昭和62年度研究報告書(班長 垂井清一郎), 1987, pp26-34
24) 馬渕 宏:家族調査により確定診断した家族性複合型高脂血症の血清脂質と冠動脈硬化症. 厚生省特定疾患調査研究原発性高脂血症調査研究班平成10年度研究報告(班長 北 徹), 1999, pp24-28

8 ◎ combined hyperlipidemiaの成因

P.108 掲載の参考文献
2) Grundy SM, Chait A, Brunzell JD:Familial combined hyperlipidemia workshop. Arteriosclerosis 7:203-207, 1987
6) Coresh J, Beaty TH, Kwiterovich PO et al:Pedigree and sib-pair linkage analysis suggest the apolipoprotein B gene is not major gene influencing plasma apolipoprotein B levels. Am J Hum Genet 50:1038-1045, 1992
14) Hayden MR, Kirk H, Clark C et al:DNA polymorphisms in and around the apo-A1-C III genes and genetic hyperlipidemia. Am J Hum Genet 40:421-430, 1987
17) Dallinga-Thie GM, Bu X-D, Van Linde-Sibenius Trip M et al:Apolipoprotein A-I/C-III/ A-IV gene cluster in familial combined hyperlipidemia:effects on LDL-cholesterol and apolipoprotein B and C-III . J Lipid Res 37:136-147, 1996
20) Beaty TH, Kwiterovich PO, Laville A et al:Genetic analysis of total cholesterol and triglycerides in a pedigree of St. Thomas rabbits. J Lipid Res 30:387-394, 1989
22) Masucci-Magoulas L, Goldberg IJ, Bisgaier CL et al:A mouse model with teatures of familial combined hyperlipidemia. Science 275:391-394, 1997
P.115 掲載の参考文献
3) Nikkila EA, Aro A:Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet 1:954-959, 1973
12) Coresh J, Beaty TH, Kwiterovich Jr PO et al:Pedigree and sib-pair linkage analysis suggest the apolipoprotein B gene is not the major gene influencing plasma apolipoprotein B levels. Am J Hum Genet 50:1038-1045, 1992
13) Aguilar-Salinas CA, Hugh P, Barrett R et al:A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy. Arterioscler Thromb Vasc Biol 17:72-82, 1997
15) Bredie SJ, Tack CJ, Smits P et al:Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives. Arterioscler Thromb Vasc Biol 17:1465-1471, 1997
22) Nakamura T, Tokunaga K, Shimomura I et al:Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107:239-246, 1994
28) 藤岡滋典ほか:肥満におけるインスリン感受性の検討. 第10回日本肥満学会記録 68, 1990
29) Fujioka S, Matsuzawa Y, Tokunaga K et al:Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. Int J Obes Relat Metab Disord 15:853-859, 1991
31) Keno Y, Matsuzawa Y, Tokunaga K et al:High sucrose diet increases visceral fat accumulation in VMH-lesioned obese rats. Int J Obes Relat Metab Disord 15:205-211, 1991

9 ◎ TG-richリポ蛋白の代謝

P.129 掲載の参考文献
2) Havel RJ, Goldstein JL, Brown MS:Lipoproteins and lipid transport. Metabolic Control and Disease (Bondy PK, Rosenberg LE ed) , WB Saunders, Philadelphia, 1980, pp393-494
3) Kane JP, Havel RJ:Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. The Metabolic and molecular Bases of inherited disease (Scriver CR, Beaudet AL, Sly WS et al ed) , McGraw-Hill, Inc. , New York, 1995, pp1853-1885
4) Mayes PA:Metabolism of Lipid. Harper's review of biochemistry (Martin DW, Mayes PA, Rodwell VW ed) , 19th ed, Lange Medical Publications, Maruzen Asia, 1983, pp201-247
5) Havel RJ, Kane JP:Introduction:structure and metabolism of plasma lipoproteins. The Metabolic and molecular Bases of inherited disease(Scriver CR, Beaudet AL, Sly WS et, aled) , McGraw-Hill, Inc. , New York, 1995, pp1841-1851
6) 池田康行, 山本 章:酵素の働き-代謝マップ上の各種酵素の作用部位と異常. わかりやすい脂質代謝とその異常(五島雄一郎編), メディカルトリビューン, 東京, 1991, pp24-27
10) Martin GA, Busch SJ, Meredith GD et al:Isolation and cDNA sequence of human postheparin plasma hepatic triglyceride lipase. J Biol Chem 263:10907-10914, 1988
17) Glomset JA, Assmann G, Gjone E et al:Lecithin:cholesterol acyltransferase deficiency and fish eye disease. The Metabolic and molecular Bases of inherited disease(Scriver CR, Beaudet AL, Sly WS et al ed) , McGraw-Hill, Inc. , New York, 1995, pp1933-1951
21) Brunzell JD:Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. The Metabolic and molecular Bases of inherited disease (Scriver CR, Beaudet AL, Sly WS et al ed) , 6th ed, McGraw-Hill, Inc. , New York, 1995, pp1128-1180
22) Takagi A, Ikeda Y, Mori A et al:A newly identified heterozygous lipoprotein lipase gene mutation (Cys239→stop/TGC972→TGA;LPLobama) in a patient with primary type IV hyperlipoproteinemia. J Lipid Res 35:2008-2018, 1994
24) 堤 善多ほか:低リポ蛋白リパーゼ群でのアルコールによる内因性高トリグリセライド血症の発症-禁酒による正脂血化-. 日本消化器病学会誌 92:951, 1995
28) Deckelbaum RJ, Olivecrona T, Eisenberg S:Plasma lipoproteins in hyperlipidemia:roles of neutral lipid exchange and lipase. Treatment of Hyperlipoproteinemia (Carlson LA, Olsson AG ed) , Raven Press, New York, 1984, pp85-93
29) Ikeda Y, Ashida Y, Takagi A et al:Mechanism of the production of small dense LDL (sLDL) in hypertriglyceridemia. ATHEROSCLEROSIS IX (Jacotot B, Mathe D, Fruchart JC ed) , Elsevier, Amsterdam, 1998, pp777-788

10 ◎ トリグリセライド代謝、HDL代謝と調節遺伝子

P.136 掲載の参考文献
2) Glover J:Retinol-binding proteins. Vitam Horm 31:1-42, 1973
3) Goodman DS:Vitamin A transport and retinol-binding protein metabolism. Vitam Horm 32:167-180, 1974
4) Saari JC, Bredberg L, Garwin GG:Identification of the endogenous retinoids associated with three cellular retinoid-binding proteins from bovine retina and retinal pigment epithelium. J Biol Chem 257:13329-13333, 1982
8) Bjorkegren J, Veniant M, Kim SK et al:Lipoprotein secretion and triglyceride stores in the heart. J Biol Chem, in press
11) Harrison EH, Hussain MM:Mechanisms involved in the intestinal digestion and absorption of dietary vitamin A. J Nutr 131:1405-1408, 2001
12) Suruga K, Suzuki R, Goda T et al:Unsaturated fatty acids regulate gene expression of cellular retinol-binding Protein, type II in rat jejunum. J Nutr 125:2039-2044, 1995
17) Wetterau JR, Aggerbeck LP, Bouma ME et al:Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258:999-1001, 1992
18) Shalp D, Blinderman L, Combs KA et al:Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 365:65-69, 1993
19) Lin MC, Arbeeny C, Bergquist K et al:Cloning and regulation of hamster microsomal triglyceride transfer protein. The regulation is independent from that of other hepatic and intestinal proteins which participate in the transport of fatty acids and triglycerides. J Biol Chem 269:29138-29145, 1994
22) Bjorn L, Leren TP, Ose L et al:A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein(MTP-493G/T) influences lipoprotein phenotype in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 20:1784-1788, 2000
25) Hagan DL, Kienzle B, Jamil H et al:Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators. J Biol Chem 269:28737-28744, 1994
26) Lin MC, Li JJ, Wang EJ et al:Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene. FASEB J 11:1145-1152, 1997
P.154 掲載の参考文献
1) 井上郁夫, 片山茂裕:抗高脂血症治療薬の開発の現状と臨床試験のあり方. 臨床薬理 30:729, 1999
2) 井上郁夫, 山田信博:介入試験の意味すること. 内科 79:181-182, 1997
3) 井上郁夫, 高橋慶一, 片山茂裕:耐糖能異常にみられるリポ蛋白異常. 日本臨床 54:2672-2678, 1996
4) 梅園和彦:核内受容体の構造分類と内分泌情報の統合. 日本臨床 56:1693-1698, 1998
5) 井上郁夫, 高橋慶一, 片山茂裕:フルクトース負荷ラットの肝の脂肪酸結合能へのベザフィブレートの影響. 糖尿病 37(Suppl 1):271, 1994
6) Sapone A, Peters JM, Sakai S et al:The human peroxisome proliferator-activated receptorα gene:identification and functional characterization of two natural allelic variants. J Pharmacogenetics 10:321-333, 2000
7) Flavell DM, Pineda TI, Jamshidi Y et al:Variation in the PPAR α gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 43:673-680, 2000
8) 野原 淳, 水野美保子, 井沢 郎ほか:原発性高脂血症患者におけるperoxisome proliferator-activated receptor α (PPAR α)ミスセンス変異体の同定. 動脈硬化 28 (suppl):134, 2000
9) 井上郁夫, 片山茂裕:PPAR αと脂質代謝. Progress in Medicine 19:2451-2459, 1999
10) Inoue I, Shino K, Noji S et al:Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commum 246:370-374, 1998
11) Staels B, Koenig W, Habib A et al:Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPAR γ activators. Nature 393:790-793, 1998
12) Chinetti G, Griglio S, Antonucci M et al:Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273:25573-25580, 1998
16) Inoue I, Goto S, Matsunaga T et al:The ligands/activators for peroxisome proliferator-activated receptor α (PPAR α) and PPAR γ increase Cu2+, Zn2+-superoxide dismutase (CuZn-SOD) and decrease p22phox message expressions in primary endothelial cells. Metabolism 50(1):3-11, 2001
19) Inoue I, Goto S, Mizotani K et al:Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect:reduction of mRNA levels for interleukin-1 β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPAR α) in primary endothelial cells. Life Sci 67:863-876, 2000
22) 井上郁夫, 林 健二, 溝谷香壽美ほか:スタチン系薬の核内受容体PPAR α促進作用 とフィブラート系薬の核内受容体LXR α促進作用. 動脈硬化 28(suppl):114, 2000
23) Chinetti G, Lestavel S, Bocher V et al:PPAR α and PPAR γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001

11 ◎ トリグリセライド、HDLと内皮細胞機能、マクロファージ

P.161 掲載の参考文献

12 ◎ 高トリグリセライド血症および低HDLコレステロール血症における凝固線溶反応

P.174 掲載の参考文献
1) The GUSTO investigator:An interventional randomized trial comparing four thrombolytic strategies for acute, myocardial infarction. N Engl J Med 329:673-682, 1993
2) Baj zar J, Mannuel R, Nesheim ME:Purification and characterization of TAFI, a thrombiactivatable fibrinoplysis inhibitor. J Biol Chem 270:14477-14484, 1995
12) Ameri A, Kuppuswamly MN, Basu S et al:Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 79:3219-3226, 1992
14) Juhan-Vague I, Pyke SDM, Alessi MC et al:Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94:2057-2063, 1996
15) Juhan-Vague I, Thompson SG, Jespersen J:Involvement of the hemostatic system in the insulin resistance syndrome:a study of 1500 patients with angina pectoris. Arterioscler Thromb13:1865-1873, 1993
19) Colluci M, Paramo J, Collen D:Generation in plasma of fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75:818-824, 1985
20) Hajjar KA, Hamel N:Identification and characterization of human endothelial cell menbrane binding sites fbr tissue plasminogen activator urokinase. J Biol Chem 265:2908-2916, 1990
23) Geng Y, Zhang B, Lotz Ml:Interleukin-6:A regulator of plasma protein gene expression in hepatic and non-hepatic tissues. Mol Biol Med 7:117-130, 1990
25) Bums P, Hoffman CJ, Katz JP et al:Vitamin K-dependent clotting factors are elevated in young adults who have close relatives with ischemic heart disease. J Lab Clin Med 122:720-727, 1993

13 ◎ リポ蛋白リパーゼ欠損症、肝性トリグリセライドリパーゼ欠損症

P.192 掲載の参考文献
2) Ikeda Y et al: A sandwich-enzyme immunoassay for the quantification of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma using monoclonal antibodies to the corresponding enzymes. J Lipid Res 31:1911-1924, 1990
3) 池田康行ほか:リパーゼ測定法. 最新内科学大系9 代謝疾患4 高脂血症・低脂血症 (井村裕夫, 尾形悦郎, 高久史麿, 垂井清一郎編集, 東野一弥, 山本 章専門編集), 中山書店, 東京, 1995, pp347-364
4) Brunzell JD:Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. The metabolic and molecular bases of inherited disease (Scriver CR, Beaudet AL, Sly WS et al ed) , McGraw-Hill, New York, 1995, pp 1913-1932
5) Nikkila EA:Familial lipoprotein lipase deficiency and related disorders of chylomicron metabolism. The metabolic and molecular bases of inherited disease (Scriver CR, Beaudet AL, Sly WS et al ed) , McGraw-Hill, New York, 1983, pp622-642
11) 原田満智子:リポ蛋白リパーゼ欠損症の長期栄養管理:摂取栄養素量と血中トリグリセリド濃度との関係について. 四国医誌 48:126-129, 1992
15) 高木敦子, 池田康行:リポ蛋白リパーゼ (LPL). 広範囲 血液・尿化学検査, 免疫学的検査(2), 日本臨床, 東京, 1999, p62-68
18) 池田康行ほか:高トリグリセライド血症をどう考えるか(2)リポ蛋白リパーゼ. Progress in Medicine 15:2343-2357, 1995
19) 堤 善多ほか:低リポ蛋白リパーゼ群でのアルコールによる内因性高トリグリセライド血症の発症. -禁酒による正脂血化-. 日本消化器病学会誌 92:951-959, 1995
20) Ikeda Y et al:Physiological role of human hepatic triglyceride lipase (HTGL):HTGL regulates the multiple lipoprotein metabolism of IDL, LDL, and HDL2. Multiple Risk Factors in Cardiovascular Disease (Yamamoto A ed) , Churchill Livingstone Japan, Tokyo, 1994, pp181-186
21) Breckemidge WC et al:Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis 45:161-179, 1982
23) Auwerx JH et al:Coexistence of abnormalities of hapatic lipase and lipoprotein lipase in a large family. Am J Hum Gener 46:470-477, 1990
24) Knundsen P et al:A compound heterozygote for hepatic lipase gene mutations Leu334→ Phe and Thr383→Met:correlation between hapatic lipase activity and phenotypic expression. J Lipid Res 37:825-834, 1996
25) 池田康行ほか:高トリグリセライド血症. Molecular Medicine 31:518-526, 1994
26) Lambert G et al:Hepatic lipase deficiency decreases the selective uptake of HDL-cholesterol esters in vivo. J Lipid Res 41:667-672, 2000
28) Martin GA et al:Isolation and cDNA sequence of human postheparin plasma hepatic triglyceride lipase. J Biol Chem 263:10907-10914, 1988
29) Ikeda Y et al:Mechanism of the production of small dense LDL(sLDL) in hypertriglyceridemia. In Atherosclerosis XI Proceedings of the 11th International Symposioum on Atheroscrelosis, 1998, pp777-788
31) 朝倉由加利ほか:ヒト肝性トリグリセリドリパーゼ (HTGL)生理作用の解明-甲状腺機能低下症治療前後のHTGLとリポ蛋白組成の検討. 動脈硬化 22:179-186, 1994

14 ◎ アルコールとIV型、V型高脂血症

P.201 掲載の参考文献

15 ◎ 糖尿病と高トリグリセライド血症

P.211 掲載の参考文献
3) 及川眞一, 小竹英俊:糖尿病患者における高トリグリセリド血症の動脈硬化への影響. Pharma Medica 15:113-118, 1997
6) Brooks-Wilson A et al:Mutation in ABC1 in Tangier disease and familial high-density lipoprotein deficienc. Nature Genetics 22:336-345, 1999
8) Hara H, Yokoyama S:Intraction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem 266:3080-3086, 1991
16) Kaplinsky E:Bezafibrate Infarction Prevention Study (BIP Study):第20回欧州心臓学会会議(オーストリア. ウィーン), 1998
17) Steiner G:Lipid intervention trial in diabetes. Diabetes Care 238 (Suppl 2):B49, 2000
19) Rubins HB, Robins SJ, Collins D et al:Gemfibrozil fbr the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999

16 ◎ 食後の高脂血症

P.226 掲載の参考文献
2) Zilversmit DG:Postprandial hyperlipidemia and its relation to atherosclerosis. Latent Dyslipoproteinemias and Atherosclerosis(Genes JL ed) , Raven Press, New York, 1984, pp1-8
5) 多田紀夫:レムナントリポ蛋白. The Lipid 7:38-41, 1996
6) Ross AC, Zilversmit DG:Chylomicron remnant cholesteryl esters as the major constituent of very low density lipoprotein in plasma of cholesterol fed rabbits. J Lipid Res 18:169-181, 1977
7) Melchior GW, Mahley RW, Buckhold DK:Chylomicron metabolism during dietary-induced hypercholesterolemia in dogs. Lipid Res 22:598-609, 1981
8) Goldstein JL, Ho YK, Brown MS et al:Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degeneration of hypercholesterolemic canine β-very low density lipoproteins. J Biol Chem 255:1839-1848, 1980
9) Mahley RW, Innerarity TL, Brown MS et al:Cholesteryl ester synthesis in macrophages:Stimulation byβ-very low density lipoproteins from cholesterol-fed animals of several species. J Lipid Res 21:970-980, 1980
16) Bjorkegren J, Packard CJ, Hamsten A et al:Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res 37:76-86, 1996
17) 多田紀夫, 池脇克則:食後高脂血症の診断法:脂肪負荷試験に伴う血清脂質とRLPの変化-リポ蛋白分画からの解析-. 動脈硬化 25:361-370, 1998
18) Cohn JS, Johnson EJ, Millar JS et al:Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl estersJ Lipid Res 34:2033-2040, 1993
21) 多田紀夫:レムナントリポ蛋白の動脈硬化発症メカニズム. 目でみる循環器病シリーズ 冠危険因子(松澤佑次編集), メジカルビュー社, 東京, 2000, pp36-41
26) Weintraube MS, Grosskopf I, Rassin T et al:Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease:case control study over three years. Br Med J 312:935-939, 1996
30) 池脇克則:冠動脈硬化症における脂肪負荷後のリポ蛋白代謝の検討. 動脈硬化 18:887-895, 1990
31) 多田紀夫:レムナント様リポ蛋白. 臨床検査 40:1023-1029, 1996
34) Murphy MC et al:Postprandial lipid and hormone responses to meals of varying fat contents:modulatory role of lipoprotein lipase? Eur J Clin Nutr 49:579-588, 1995
38) 多田紀夫:食後高脂血症と高レムナント血症-脂肪負荷試験の意義-. 動脈硬化 27:319-325, 2000
39) Syvanme M, Hilden H, Taskinen M-R:Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary heart disease. J Lipid Res 35:15-26, 1994
41) Bergeron N, Havel RJ:Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein ε 4allele. J Clin Invest 97:65-72, 1996
44) 多田紀夫:アポ蛋白-密度勾配電気泳動法-. 臨床検査 29:1416-1421, 1985

17 ◎ 女性ホルモンとトリグリセライド代謝、高脂血症

P.236 掲載の参考文献
1) 厚生省保険医療局疾病対策課:第4次循環器疾患基礎調査の概要, 1992
3) Colvin PL, Auerbach BJ, Case LD et al:A dose-response relationship between sex hor none-induced change in hepatic triglyceride lipase and high-density lipoprotein in postmenopausal women. Metabolism 40:1052-1056, 1991
10) 佐久間一郎:本邦閉経後女性へのホルモン補充療法における用法・用量と凝固・線溶系への影響. 高齢女性の健康増進のためのホルモン補充療法ガイドライン(大内 尉義編), メディカルレビュー社, 東京, 2001, pp240-242
13) Tchemof A, Calles-Escandon J, Sites CK et al:Menopause, central body fatness, and insulin resistance:effects of hormone-replacement therapy. Coron Artery Dis 9:503-511, 1998
14) Tchemof A, Peohlman ET, Despres JP:Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab 26:12-20, 2000
16) Brussaard HE, Gevers-Leuven JA, Kluft C et al:Effect of 17 β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus. Arterioscl Thromb Vascl Biol 17:324-330, 1997
17) Goldsland IF:The influence of female sex steroids on glucose metabolism and insulin action. Intern Med Supp1738:1-60, 1996
18) 高齢女性の健康増進のためのホルモン補充療法ガイドライン(大内尉義編), メディカルレビュー社, 東京, 2001

18 ◎ 高トリグリセライド血症の治療

P.257 掲載の参考文献
4) Rubins HB, Robins SJ, Collins D et al:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol intervention Trial Study Group. N Engl J Med 341:410-418, 1999
6) Goldbourt U, Brunner D, Behar S et al:Baseline characteristics of patients participating in the Bezafibrate infarction Prevention (BIP) Study. Eur Heart J 19 (Suppl H):H42-H47, 1998
P.269 掲載の参考文献

19 ◎ IDL、レムナント測定法

P.274 掲載の参考文献
6) Kugiyama K, Doi H, Motoyama T et al:Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 97:2519-2526, 1998
8) Kugiyama K, Doi H, Takazoe K et al:Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99:2858-2860, 1999
10) Karpe F, Boquist S, Tang R et al:Remnant lipoproteins are related to intimamedia thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 42:17-21, 2001
P.281 掲載の参考文献
1) Toshimi K et al:Lipoprotein Analysis using Agarose Gel Electrophoresis and Differential Staining of Lipids. J Atheroscler Thromb 8(1):7-13, 2001
2) 貴堂としみほか:アガロース電気泳動法によるリポ蛋白分析の臨床応用. The Lipid 9:487-494, 1998
3) 浦田武義:脂質分別定量法(酵素法). 臨床検査 29(11):1344-1352, 1985
4) 中里 功ほか:脂質電気泳動に用いる血清検体の保存方法について. 第15回サンプリング研究会講演抄録, 2001, p35
5) 大井絹枝ほか:血清コレステロール分画・トリグリセライド分画同時測定法. 検査と技術 29(8):973-979, 2001
6) Daniel LS, Michael CP:Quantitative measurement of lipoprotein surface charge by agarose gel electrophoresis. Journal Lipid Res 33:123-130, 1992
7) Michael La Belle, Patricia JB, Ronald MK:Charge properties of low density lipoprotein subclasses. Journal Lipid Res 38:690-700, 1997
8) 大井絹枝ほか:血清コレステロール分画トリグリセライド分画同時測定によるLDL分画質的異常の検討. 生物物理化学 45:83-88, 2001
9) 蔵田英明ほか:糖尿病におけるリポ蛋白異常の臨床的意義. 2001動脈硬化学会シンポジウム, p122
10) 橋本陽子ほか:糖尿病患者群を対象としたコレトリコンボにおけるLDL変性度数の検討. JJCLA 25(4):359, 2000
P.286 掲載の参考文献
2) Okazaki M, Usui S, Hosaki S:Analysis of plasma lipoproteins by gel permeation chromatography. Handbook of Lipoprotein Testing, 2nd Edition (Rifai N, Warnick GR, Dominiczak MH ed) , AACC Press, Washington DC, 2000, pp647-669
3) Usui S, Jitsukata K, Kazama H et al:Simultaneous analysis of serum lipoprotein cholesterol and triglycerides by a HPLC method. Clin Chem 46 (S6):A103, 2000

最近チェックした商品履歴

Loading...